On June 17, 2026, a leading analyst from Cantor Fitzgerald set a new price target of $61.00 for uniQure N.V. (NASDAQ:QURE). uniQure, a pioneering biopharmaceutical company specializing in innovative gene therapies, also received an Overweight rating from the firm, as highlighted by TheFly, suggesting strong potential for the stock's performance.
This optimistic outlook for uniQure follows a major regulatory breakthrough. The U.S. Food and Drug Administration (FDA) has provided a clear path forward for uniQure's groundbreaking gene therapy candidate, AMT-130. This innovative treatment is being developed to address the currently incurable Huntington's disease.
The FDA's agreement that existing data from a mid-stage study is acceptable for a Biologics License Application (BLA) marks a significant milestone. A BLA represents a formal request to market a new drug. uniQure is strategically seeking accelerated approval, a crucial program designed to facilitate earlier market access for therapies targeting serious conditions.
Following this positive FDA meeting, uniQure now plans to submit its BLA in the third quarter of 2026. As reported by Reuters, this submission is a critical step toward potentially bringing the first-ever gene therapy for Huntington's disease to patients globally who urgently need effective treatment options.
This positive news caused a significant surge in investor confidence and robust buying activity. uniQure's stock price impressively increased by 78.44% to $48.16 on a high trading volume of 19.58 million shares. At the time the analyst target was initially set, the stock was trading at $47.40, indicating a substantial potential upside of 28.69%.
